This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| INSERM Unit U1217 | |
|---|---|
| Name | INSERM Unit U1217 |
| Established | 2014 |
| Type | Research unit |
| Parent institution | Institut National de la Santé et de la Recherche Médicale |
| Location | Bordeaux, France |
| Director | Alain Thierry |
| Staff | ~100 |
INSERM Unit U1217 is a biomedical research unit within the French Institut National de la Santé et de la Recherche Médicale focused on translational oncology and molecular pathology. Located in Bordeaux and affiliated with regional hospitals and universities, the unit develops diagnostic assays, biomarker discovery programs, and therapeutic strategies that bridge basic science and clinical practice. It maintains a multidisciplinary portfolio spanning molecular biology, genomics, bioinformatics, and clinical trials.
The unit was created under the aegis of INSERM during restructuring efforts that followed national research reforms and the expansion of translational research initiatives in the 2010s. Founding activities drew on legacy groups from the University of Bordeaux and the CHU de Bordeaux to consolidate expertise in cancer genetics and liquid biopsy. Over its history the unit has participated in national programs tied to the Plan Cancer and EU projects coordinated with institutions such as the European Molecular Biology Laboratory, Institut Curie, and CNRS. Leadership transitions have paralleled collaborations with clinical networks at the Institut Bergonié and participation in consortia linked to the European Research Council and the Horizon 2020 framework.
Research programs concentrate on oncological biomarkers, circulating tumor DNA, extracellular vesicles, and targeted therapeutics. Projects integrate high-throughput sequencing platforms used in collaborations with the Wellcome Sanger Institute and the Broad Institute, and employ computational pipelines influenced by methods developed at European Bioinformatics Institute and Inria. Translational efforts align with clinical trials registered with ClinicalTrials.gov and guided by recommendations from agencies such as the Haute Autorité de Santé and the European Medicines Agency. The unit's work intersects with molecular pathology initiatives connected to the World Health Organization coding systems and with precision oncology consortia including the International Cancer Genome Consortium and the Cancer Research UK network.
Organizational structure is typical of INSERM units, with research teams grouped around thematic programs overseen by a director and deputy directors. Scientific governance engages academic partners from the University of Bordeaux, clinical leads from the CHU de Bordeaux, and advisory input from national bodies like the Ministry of Solidarity and Health and the Agence Nationale de la Recherche. Leadership has included recognized investigators who have collaborated with laboratories at Institut Pasteur, École Normale Supérieure, and international centers such as Johns Hopkins University and Massachusetts General Hospital.
The unit maintains partnerships with university hospitals in the Nouvelle-Aquitaine region and with national research organizations including the CNRS and CEA. International collaborations involve networks like the European Cancer Organisation, the Ludwig Institute for Cancer Research, and academic centers including Karolinska Institutet, University of Cambridge, and University of California, San Francisco. Industry partnerships include diagnostics and biotech firms with ties to the European Investment Bank funding schemes and venture initiatives associated with Bpifrance. The unit is active in consortia that have links to philanthropic funders such as the Fondation ARC and to multinational clinical research organizations.
Laboratory infrastructure incorporates genomics platforms, proteomics units, cell culture suites, and biobanking facilities affiliated with the regional tumor bank recognized under the French Biobanque network. Core facilities mirror standards from international cores at the Max Planck Society and the National Institutes of Health, providing next-generation sequencing, mass spectrometry, flow cytometry, and imaging modalities. Clinical sample access is facilitated through agreements with the CHU de Bordeaux and the regional cancer center Institut Bergonié, enabling translational pipelines from patient recruitment to molecular analysis.
The unit has published articles in high-impact journals and collaborated on multi-center studies reported in outlets linked to publishers such as Nature Publishing Group, Springer Nature, and Elsevier. Contributions include advances in circulating tumor DNA detection methodologies, extracellular vesicle biomarker characterization, and molecular diagnostics validated in cohorts drawn from European multicenter trials. Work has cited frameworks and standards from organizations like the American Society of Clinical Oncology and the College of American Pathologists and has been presented at conferences including the American Association for Cancer Research and the European Society for Medical Oncology.
Funding sources comprise competitive grants from the Agence Nationale de la Recherche, project awards from the European Commission under programs such as Horizon 2020, investigator grants from the European Research Council, and institutional support from INSERM and the University of Bordeaux. Additional funding streams include philanthropic grants from entities like the Fondation pour la Recherche Médicale, collaborative funding with industry partners, and regional development funds administered by the Nouvelle-Aquitaine Region.